Inflammatory bowel disease in the pediatric and adolescent patient

Gastroenterology Clinics of North America

Volumn 31, Issue 1, 2002, Pages 275-291

  Cuffari, C ^a   Darbari, A ^a  

^a JOHNS HOPKINS CHILDREN S CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GADOLINIUM; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADOLESCENT; BONE MARROW DEPRESSION; CHILD; CLINICAL FEATURE; CROHN DISEASE; DRUG MONITORING; ENTERITIS; ENVIRONMENTAL FACTOR; HEPATITIS; HEREDITY; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PARESTHESIA; PATHOGENESIS; PHENOTYPE; RASH; REVIEW; SEROLOGY; SUPERINFECTION; TREATMENT OUTCOME; TREMOR; ULCERATIVE COLITIS; AGE; ENVIRONMENTAL EXPOSURE; GENETICS; IMMUNOLOGY;

ADOLESCENT; AGE FACTORS; CHILD; ENVIRONMENTAL EXPOSURE; HUMAN; IMMUNOSUPPRESSION; INFLAMMATORY BOWEL DISEASES; HUMANS;

EID: 0035986146     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(01)00017-6     Document Type: Article

References (86)

1. 6-Thioguanine levels versus white blood cell counts in guiding 6-mercaptopurine and azathioprine therapy
2. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis
3. Clinical features morbidity and mortality of Scottish children with inflammatory bowel disease
4. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease
5. Thiopurine methyl transferase predicts therapy-limiting severe toxicity from azathioprine
6. Linkage heterogeneity for the IBD 1 locus in Crohn's disease pedigrees by disease onset and severity
7. Clinical manifestations of Crohn's disease in children and adolescents
8. Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16
9. Confirmation of a subceptibility locus IBD 1 for Crohn's disease on chromosome 16
10. Crohn's disease: Influence of age at onset on clinical phenotype
11. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with IBD
12. 6-Mecraptopurine metabolites tailored to achieve clinical responsiveness in pediatric IBD
13. 6-Mecraptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity
14. Mesalamine in pediatric inflammatory bowel disease: A 10-year experience
15. Gadolinium enhanced magnetic resonance imaging (G-MRI) in diagnosing pediatric IBD
16. Optimizing and individualizing 6-MP therapy in IBD: The role of 6-MP metabolite levels and TPMT genotyping
17. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease
18. Associations between HLA-DR alleles and subsets of ulcerative colitis defined by extent of colitis
19. Magnetic resonance imaging to distinguish the type and severity of IBD
20. Perinatal risk factors for inflammatory bowel disease: A case-control study
21. Crohn's disease following measles virus exposure in utero: Risk estimates and clinical characteristics
22. Perinatal measles infection and subsequent Crohn's disease
23. The pharmacology of azathioprine
24. Altered mercaptopurine metabolism toxic effects and dosage requirements in a thiopurine methyl transferase deficient child with acute lymphoblastic leukemia
25. Methotrexate for the treatment of Crohn's disease
26. Methotrexate therapy in children with severe Crohn's disease: Preliminary results
27. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease
28. Gastrointestinal manifestations of primary immunodeficiency disorders
29. Mapping inflammatory bowel disease genes: Complications of study design and population structure
30. Linkage to a susceptibility region on chromosome 12 but not 16 in a North central European family sample by multi-point non-parametric linkage analysis
31. Epidemiological study confirms association of IBD 1 with Crohn's disease
32. Mapping a susceptibility locus for Crohn's disease on chromosome 16
33. Use of infliximab in the treatment of Crohn's disease in children and adolescents
34. Azathioprine in ulcerative colitis: Final report on a controlled therapeutic trial
35. The pharmacology and clinical use of methotrexate
36. Cyclosporine
37. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease
38. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease
39. Inflammatory bowel disease
40. Long-term use of methotrexate in inflammatory bowel disease: Severe disease 3 drug therapy 2: Seventh inning stretch
41. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
42. The clinical pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia
43. Variable mercptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
44. Crohn's disease of the upper gastrointestinal tract
45. Persistent measles virus infection of the intestine: Confirmation by immunogold electron microscopy
46. Cyclosporine in severe ulcerative colitis refractory to steroid therapy
47. Arthritis associated with inflammatory bowel disease
48. Methotrexate in patients with Crohn's disease after 6-mercaptopurine
49. Cyclosporine and 6-mercaptopurine for active refractory Crohn's colitis in children
50. A multicenter trial of 6-mercaptopurine and prednisone therapy in children with newly diagnosed Crohn's disease
51. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease
52. Ankylosing spondylitis and chronic inflammatory bowel diseases of the intestines
53. The epidemiology of inflammatory bowel disease
54. The epidemiology of idiopathic inflammatory bowel disease
55. Nutritional management of inflammatory bowel disease
56. Growth failure in children with inflammatory bowel disease: A prospective study
57. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease but not ulcerative colitis
58. The pharmacology of methotrexate
59. Azathioprine and 6-mercaptopurine in Crohn's disease: A meta-analysis
60. 6-Mercaptopurine in the management of inflammatory bowel disease: Short and long-term toxicity
61. Infliximab for the treatment of fistulas in patients with Crohn's disease
62. A high incidence of chronic inflammatory bowel disease in patients with Turner's syndrome
63. A controlled trial of azathioprine in the management of chronic ulcerative colitis
64. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease
65. Efficacy and safety of pretreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
66. Genetics of inflammatory bowel disease
67. Inflammatory bowel disease
68. Epidemiology of Crohn's disease in Regio Leiden The Netherlands: A population study from 1979-1983
69. Comparison of magnetic resonance imaging and endoscopy in distinguishing the type and severity of inflammatory bowel disease
70. Magnetic resonance imaging in inflammatory bowel disease
71. Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease
72. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha antibody for Crohn's disease
73. Genetic versus environment in inflammatory bowel disease: Results of a British twin study
74. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells
75. Cyclosporine treatment of severe ulcerative colitis in children
76. Azathioprine pharmacokinetics after intravenous oral delayed release oral and rectal foam administration
77. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics
78. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup
79. Azathioprine in the treatment of children with inflammatory bowel disease
80. Crohn's disease: Pathogenesis and persistent measles virus infection
81. Evidence of persistent measles virus infection in Crohn's disease
82. Severe colitis in children and adolescents: Diagnosis course and treatment
83. Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis
84. Familial empiric risks for inflammatory bowel disease: Differences between Jew and non-Jews
85. Crohn's disease of the proximal small intestine: Radiological findings in 55 patients